Literature DB >> 231299

Comparison of pivmecillinam and cephradine in bacteriuria in pregnancy and in acute urinary tract infection.

W Brumfitt, I Franklin, J Hamilton-Miller, F Anderson.   

Abstract

48 non-pregnant domiciliary patients referred by general practitioners and 50 pregnant women were treated for bacteriuria with either 500 mg cephradine or 400 mg pivmecillinam every 6 h for 7 days. In the pregnant women, cure rates were over 90% after 2 weeks for both compounds, and after 6 weeks were 86% for cephradine and 78% for pivmecillinam. Cure rates in the non-pregnant were 83% for cephradine and 95% for pivmecillinam at 6 weeks. Seven patients (3 given cephradine, 4 given pivmecillinam) stopped treatment due to side-effects. Overall, side-effects (many of which were trivial) were more common in patients treated with cephradine (51%) than in those receiving pivmecillinam (33%). It is concluded that both drugs are highly effective in these two common types of urinary infection.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 231299     DOI: 10.3109/inf.1979.11.issue-4.04

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  4 in total

1.  The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women.

Authors:  A Heikkilä; K Pyykkö; R Erkkola; E Iisalo
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

2.  Recurrent urinary infections in women: clinical trial of cephradine as a prophylactic agent.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 3.  Treatments for symptomatic urinary tract infections during pregnancy.

Authors:  Juan C Vazquez; Edgardo Abalos
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

4.  Pivmecillinam in complicated urinary infections failing to respond to conventional therapy.

Authors:  W Brumfitt; J M Hamilton-Miller
Journal:  Infection       Date:  1982       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.